I think most on this board appreciate your input on financials, at least I do and several others here have expressed the same. The issue with financials in a company like this is that they in no way can reflect the true potential of this company. Many who hold to strict investment strategies based around financials miss out on the big picture opportunity because they simply do not comprehend the significance of what a company like this has to offer past the ongoing need for financing and the other news cycles that go with that which is what makes most small biotechs trading stocks. Many folks I know base their investment decisions on the easiest to evaluate and agree upon information that comes from the required reporting done by companies. They simply won’t invest in a company like this because of this no matter how good everything else looks. They are willing to wait for the “easy money” derisked investment when if they had carefully considered all the other factors they might have understood that derisking had already taken place and then invested earlier to achieve a 100 fold increase over time instead of 5-10x over the same amount of time. To each their own. Best wishes.
Many looking at stocks don’t invest in a company with a high or no PE. Therefore , no one with that investing thesis would ever look at a stock in the developing biotech industry with no product bringing revenue at this stage.
Developmental biotechs rarely have revenue. Some have sweetheart deals with BP, most do not. That does not make them a bad investment or uninvestable, it just means that investors need to know how to manage that risk and know what they are doing. They can be some of the most rewarding investments available, akin to private equity investments, when they work out. But they are not for everyone and not for your average retail investor probably.
News 
Market Data 
Discover 
